493 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Sell
Article Searches
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336 Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Top Analyst Reports for Chevron, IBM & Medtronic http://www.zacks.com/research-daily/368238/top-analyst-reports-for-chevron-ibm-medtronic?cid=CS-ZC-FT-368238 Apr 01, 2019 - Top Analyst Reports for Chevron, IBM & Medtronic
3 Big Pharma Stocks to Add to Your Portfolio This April http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171 Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
GSK Prescribes A $3.5bn Bond In 3 Parts https://seekingalpha.com/article/4250143-gsk-prescribes-3_5bn-bond-3-parts?source=feed_all_articles Mar 21, 2019 - British pharma giant GlaxoSmithKline joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt.The UK-based firm priced US$3.5bn worth of ‘A’-rated, three-, five- and
Emergent Begins Phase III Study on Anthrax Vaccine AV7909 http://www.zacks.com/stock/news/362304/emergent-begins-phase-iii-study-on-anthrax-vaccine-av7909?cid=CS-ZC-FT-362304 Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Glaxo Presents Encouraging Data on Endometrial Cancer Drug http://www.zacks.com/stock/news/362265/glaxo-presents-encouraging-data-on-endometrial-cancer-drug?cid=CS-ZC-FT-362265 Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million http://www.zacks.com/stock/news/360866/novartis-nvs-alcon-acquired-powervision-for-%24285-million?cid=CS-ZC-FT-360866 Mar 18, 2019 - Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy http://www.zacks.com/stock/news/358436/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358436 Mar 08, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Top Research Reports for Microsoft, Mastercard & General Electric http://www.zacks.com/research-daily/228770/top-research-reports-for-microsoft-mastercard-general-electric?cid=CS-ZC-FT-228770 Mar 08, 2019 - Top Research Reports for Microsoft, Mastercard & General Electric
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy http://www.zacks.com/stock/news/358194/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358194 Mar 07, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Pages: 1234567...50

<Page 2>